Abstract:In the clinical treatment of fractures, rhBMP-2 administration is associated with a well-established profile of side-effects, including osteolysis and ectopic bone formation, which are driven by pro-inflammatory processes triggered by the use of high doses. Immunomodulatory strategies could minimize the incidence of side-effects by enabling the use of lower, and safer, rhBMP-2 doses. This study investigated whether interleukin-1 receptor antagonist (IL-1Ra) can enhance the therapeutic efficacy of a low dose of rhBMP-2 in a weight-bearing femoral fracture healing model. Exogenous IL-1Ra, in combination with rhBMP-2, was delivered using a collagen-hydroxyapatite scaffold (CHA) to attenuate IL-1β produced in response to fracture. Femoral defects were treated with CHA scaffolds alone, or loaded with IL-1Ra (2.5 µg), rhBMP-2 (1 µg), IL-1Ra (2.5 µg) in combination with rhBMP-2 (1 µg). Bone healing was assessed over 14 weeks in comparison to control groups, empty defect, and a higher dose of rhBMP-2 (5 µg), which were recently demonstrated to lead to non-union, and successful bridging of the defect, respectively. The combination of IL-1Ra and rhBMP-2 led to significantly faster early bone formation, at both week 4 and 6, compared to a low dose of rhBMP-2 alone. By 14 weeks, the combination of IL-1Ra and a rhBMP-2 promoted full bridging of femurs, which were 3-fold more mechanically reliable compared to the femurs treated with a low dose of rhBMP-2 alone. Taken together, this study demonstrates that IL-1Ra can significantly enhance femoral bone healing when used in combination with a low dose of rhBMP-2. STATEMENT OF SIGNIFICANCE: Enabling the use of lower and safer doses of rhBMP-2, a potent inducer of bone formation, is of clinical relevance in orthopaedic medicine. In this study, the immunomodulatory interleukin-1 receptor antagonist (IL-1Ra) was investigated for its capacity to enhance the therapeutic efficacy of rhBMP-2 when used at lower doses in a weight-bearing femoral fracture healing model. The combination of IL-1Ra and rhBMP-2 led to significantly faster early bone formation, and resulted in more mechanically reliable healed femurs, compared to a low dose of rhBMP-2 alone. This demonstrates for the first time in a rat long bone healing model that IL-1Ra can significantly enhance bone healing when used in combination with a low dose of rhBMP-2.

IL-6 potentiates BMP-2-induced osteogenesis and adipogenesis via two different BMPR1A-mediated pathways

Synergy Between IL-6 and Soluble IL-6 Receptor Enhances Bone Morphogenetic Protein-2/Absorbable Collagen Sponge-Induced Bone Regeneration Via Regulation of BMPRIA Distribution and Degradation.

Tgf-Beta and Bmp Signaling in Osteoblast, Skeletal Development, and Bone Formation, Homeostasis and Disease

Opposing TNF-α/IL-1β- and BMP-2-activated MAPK Signaling Pathways Converge on Runx2 to Regulate BMP-2-induced Osteoblastic Differentiation

Exaggerated Inflammatory Environment Decreases BMP-2/ACS-induced Ectopic Bone Mass in a Rat Model: Implications for Clinical Use of BMP-2

Interleukin-6/interleukin-6 receptor complex promotes osteogenic differentiation of bone marrow-derived mesenchymal stem cells

The Immunomodulatory Role of BMP-2 on Macrophages to Accelerate Osteogenesis

Regulating macrophage-MSC interaction to optimize BMP-2-induced osteogenesis in the local microenvironment

IL-6 Promotes Low Concentration of RANKL-induced Osteoclastic Differentiation by Mouse BMMs Through Trans-Signaling Pathway

BMP-6 promotes type 2 immune response during enhancement of rat mandibular bone defect healing

The roles of bone morphogenetic proteins and their signaling in the osteogenesis of adipose-derived stem cells.

Endogenous bone morphogenetic protein 2 plays a role in vascular smooth muscle cell calcification induced by interleukin 6 in vitro

Synergism of rhBMP-2, TGF-β and bFGF in osteoindution and osteogenesis

IL-1β promotes osteogenic differentiation of mouse bone marrow mesenchymal stem cells via the BMP/Smad pathway within a certain concentration range

Interleukin-1 receptor antagonist enhances the therapeutic efficacy of a low dose of rhBMP-2 in a weight-bearing rat femoral defect model

Synergistic Effect of RhBMP-2 and Bfgf on Ectopic Osteogenesis in Mice.

Synergistic Effect of Nanomaterials and BMP-2 Signalling in Inducing Osteogenic Differentiation of Adipose Tissue-Derived Mesenchymal Stem Cells.

Interleukin-35 Promote Osteogenesis and Inhibit Adipogenesis: Role of Wnt/β-Catenin and PPARγ Signaling Pathways

LPS-stimulated Inflammatory Environment Inhibits BMP-2-induced Osteoblastic Differentiation Through Crosstalk Between TLR4/MyD88/NF-κB and BMP/Smad Signaling.

Leptin Potentiates BMP9-Induced Osteogenic Differentiation of Mesenchymal Stem Cells Through the Activation of JAK/STAT Signaling.

Heterodimeric BMP-2/7 Exhibits Different Osteoinductive Effects in Human and Murine Cells